HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy

Antiviral Therapy

Volumn 13, Issue 4, 2008, Pages 519-527

  Tamburrini, Enrico ^a   Ravizza, Marina ^b   Floridia, Marco ^c   Tibaldi, Cecilia ^d   Alberico, Salvatore ^e   Anzidei, Gianfranco ^f   Maccabruni, Anna ^g   Meloni, Alessandra ^h   Degli Antoni, Anna ⁱ   Mori, Fernanda ^j   Dalzero, Serena ^b   Conserva, Valentino ^k   Pinnetti, Carmela ^a   Ferrazzi, Enrico ^k  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Policlinic Hospital   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h UNIVERSITY OF CAGLIARI   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j AUSL   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; BIRTH DEFECT; CD4 LYMPHOCYTE COUNT; CONCEPTION; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, FIRST; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 47649109370     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494.
2. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20:1419-1427.
3. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV yransmission in the United States - November 2, 2007. (Updated 27 May 2008. Accessed 28 May 2008.) Available from http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.
4. Floridia M, Tamburrini E, Ravizza M, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther 2006; 11:941-946.
5. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-393.
6. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
7. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007; 20:22-32.
8. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007; 8:1-8.
9. Duran AS, Losso MH, Salomon H, et al. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 2007; 21:199-205.
10. European Collaborative Study, Patel D, Cortina-Borja M, et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647-1656.
11. Louis JM, Buhari MA, Blackwell SC, et al. Characteristics associated with suboptimal viral suppression at delivery in human immunodeficiency virus-1-infected pregnant women. Am J Obstet Gynecol 2005; 193:1266-1269.
12. Read JS, Cahn P, Losso M, et al. Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites. Obstet Gynecol 2007; 109:1358-1367.
13. Saada M, Le Chenadec J, Berrebi A, et al. Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS 2000; 14:2355-2360.
14. Martin F, Navaratne L, Khan W, et al. Pregnant women with HIV infection can expect healthy survival: three-year follow-up. J Acquir Immune Defic Syndr 2006; 43:186-192.
15. Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 2007; 196:1044-1052.
16. Antiretroviral Pregnancy Registry 2005. Interim Report (issued December 2007). (Updated 23 May 2008. Accessed 28 May 2008.) Available from http://www.apregistry.com
17. Townsend CL, Tookey PA, Cortina-Borja M, Peckham CS. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 2006; 42:91-94.
18. Watts DH, Li D, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44:299-305.
19. Bellon Cano JM, Sanchez-Ramon S, Ciria L, et al. The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain. Med Sci Monit 2004; 10:79-84.